Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

RSS icon
Thumbnail

Robotic catheter paves the way for combo valve procedures

A novel robotic catheter could simplify valve procedures while allowing cardiac surgeons to complete multiple interventions within the same time frame, according to research presented at TVT 2019 in Chicago.

Transcarotid access: The future of non-femoral TAVR?

Research presented at TVT 2019 in Chicago last week suggests a transcarotid approach to transcatheter aortic valve replacement is favorable for patients unable to tolerate femoral access, topping both transapical and transaortic approaches as the preferable route for alternate-access TAVR.  

Thumbnail

Why the next TAVR vs. SAVR trial should be in bicuspid AS patients

Physicians are facing a new issue as TAVR expands to younger populations—an increased incidence of bicuspid aortic stenosis.

‘Our patients are worth it’: Tackling the undertreatment of aortic stenosis in the US

The undertreatment of aortic stenosis in the U.S. is severe, driven by deep-rooted racial and sex disparities and a disconnect between patients and their clinicians.

Thumbnail

Valve-in-valve TAVR proves successful in the long-term

An analysis of PARTNER 2 data, published in the June edition of the Journal of the American College of Cardiology, suggests transcatheter aortic valve replacement (TAVR) within failed bioprosthetic surgical aortic valves is a viable long-term solution for high-risk individuals, with patients seeing “excellent” functional and quality of life outcomes three years after the procedure.

Thumbnail

TAVR outcomes worse in patients with end-stage renal disease

Patients with end-stage renal disease (ESRD) face higher risks of in-hospital mortality and bleeding with transcatheter aortic valve replacement (TAVR) than patients who aren’t dialysis-dependent, researchers report in the Journal of the American College of Cardiology.

COAPT: Patients with HF, mitral regurgitation see better health outcomes with TMVR

A recent analysis of the COAPT trial, published this spring in the Journal of the American College of Cardiology, suggests patients with symptomatic heart failure (HF) and secondary mitral regurgitation (MR) might see better mental and physical outcomes if they’re treated with edge-to-edge transcatheter mitral valve repair (TMVR) in lieu of standard therapy.

Thumbnail

Abbott’s tricuspid valve repair system finds success in TRILUMINATE study

Results from the TRILUMINATE study, presented this week at EuroPCR 2019 in Paris, suggest Abbott’s minimally invasive tricuspid valve repair system is an effective solution for patients with structural heart disease, reducing the severity of tricuspid regurgitation (TR) in more than 85% of test cases.

Displaying 729 - 736 of 2332

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.